AbCellera Biologics (ABCL) Cash from Operations: 2020-2025
Historic Cash from Operations for AbCellera Biologics (ABCL) over the last 6 years, with Sep 2025 value amounting to -$52.6 million.
- AbCellera Biologics' Cash from Operations fell 82.10% to -$52.6 million in Q3 2025 from the same period last year, while for Sep 2025 it was -$104.6 million, marking a year-over-year increase of 12.99%. This contributed to the annual value of -$108.6 million for FY2024, which is 147.41% down from last year.
- Per AbCellera Biologics' latest filing, its Cash from Operations stood at -$52.6 million for Q3 2025, which was down 62.31% from -$32.4 million recorded in Q2 2025.
- In the past 5 years, AbCellera Biologics' Cash from Operations registered a high of $273.0 million during Q2 2022, and its lowest value of -$126.8 million during Q3 2022.
- Its 3-year average for Cash from Operations is -$22.6 million, with a median of -$28.9 million in 2024.
- As far as peak fluctuations go, AbCellera Biologics' Cash from Operations surged by 14,438.35% in 2021, and later slumped by 27,147.17% in 2024.
- AbCellera Biologics' Cash from Operations (Quarterly) stood at -$16.7 million in 2021, then spiked by 284.97% to $30.9 million in 2022, then slumped by 163.44% to -$19.6 million in 2023, then spiked by 59.21% to -$8.0 million in 2024, then tumbled by 82.10% to -$52.6 million in 2025.
- Its last three reported values are -$52.6 million in Q3 2025, -$32.4 million for Q2 2025, and -$11.6 million during Q1 2025.